|
FDA Panel Supports J&J’s Remicade for Pediatric Ulcerative Colitis
An FDA advisory committee has voted in favor of expanding use of Johnson & Johnson’s (J&J) Remicade to pediatric patients with ulcerative colitis (UC) but says more data is needed to determine the drug’s long-term effects.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives